 |
 |
|
7 October 2003 | Volume 139 Issue 7 | Pages 539-546
Background: Gastrointestinal (GI) toxicity mediated by dual cyclooxygenase (COX)-1 and COX-2 inhibition of nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious alterations of mucosal integrity or, more commonly, intolerable GI symptoms that may necessitate discontinuation of therapy. Unlike NSAIDs, rofecoxib targets only the COX-2 isoform.
Objective: To assess the tolerability of rofecoxib compared with naproxen for treatment of osteoarthritis.
Design: Randomized, controlled trial.
Setting: 600 office and clinical research sites.
Patients: 5557 patients (mean age, 63 years) with a baseline diagnosis of osteoarthritis of the knee, hip, hand, or spine.
Intervention: Rofecoxib, 25 mg/d, or naproxen, 500 mg twice daily. Use of routine medications, including aspirin, was permitted.
Measurements: Discontinuation due to GI adverse events (primary end point) and use of concomitant medication to treat GI symptoms (secondary end point). Efficacy was determined by patient-reported global assessment of disease status and the Australian/Canadian Osteoarthritis Hand Index, as well as discontinuations due to lack of efficacy. Patients were evaluated at baseline and at weeks 6 and 12.
Results: Rates of cumulative discontinuation due to GI adverse events were statistically significantly lower in the rofecoxib group than in the naproxen group (5.9% vs. 8.1%; relative risk, 0.74 [95% CI, 0.60 to 0.92]; P = 0.005), as were rates of cumulative use of medication to treat GI symptoms (9.1% vs. 11.2%; relative risk, 0.79 [CI, 0.66 to 0.96]; P = 0.014]). Subgroup analysis of patients who used low-dose aspirin (13%) and those who previously discontinued using arthritis medication because of GI symptoms (15%) demonstrated a relative risk similar to the overall sample for discontinuation due to GI adverse events (relative risk, 0.56 [CI, 0.31 to 1.01] and 0.53 [CI, 0.34 to 0.84], respectively). No statistically significant difference was observed between treatments for efficacy in treating osteoarthritis or for occurrence of other adverse events.
Conclusions: In patients with osteoarthritis treated for 12 weeks, rofecoxib, 25 mg/d, was as effective as naproxen, 500 mg twice daily, but had statistically significantly superior GI tolerability and led to less use of concomitant GI medications. Benefits of rofecoxib in subgroup analyses were consistent with findings in the overall sample.
*For members of the ADVANTAGE (Assessment of Differences between Vioxx and Naproxen To Ascertain Gastrointestinal Tolerability and Effectiveness) Study Group, see the Appendix.
Editors' Notes
Context
Contribution
Cautions
–The Editors
Author and Article Information
From University of Arizona, Tuscon, Sun Valley Arthritis Center, Ltd., Glendale, and Southwest Health Institute, Phoenix, Arizona; Scripps Clinic, La Jolla, California; Uppsala University, Uppsala, Sweden; Ormond Medical Arts, Ormond Beach, Florida; and Merck & Co., Inc., West Point, Pennsylvania.
Acknowledgments: The authors thank Drs. John Yates, Thomas Dobbins, Desmond Thompson, Richard Petruschke, Douglas Watson, and Walter Straus for reviewing this manuscript and for providing helpful comments. They also thank Dr. Nicholas Bellamy for providing the AUSCAN Osteoarthritis Hand Index and Drs. Thomas Schnitzer, Marc Hochberg, Arthur Weaver, Walter Straus, and Glenn Gormley for their input into study design. In addition, they gratefully acknowledge the contribution of Kathy O'Brien for assistance with manuscript preparation and for comonitoring this trial and Dr. Martino Laurenzi for comonitoring sites outside the United States.
Grant Support: By Merck & Co., Inc.
Potential Financial Conflicts of Interest: Employment: C.S. Skalky (Merck and Co., Inc.), M.E. Dixon (Merck and Co., Inc.), A.B. Polis (Merck and Co., Inc.), G.P. Geba (Merck and Co., Inc.); Consultancies: J.R. Lisse (Merck and Co., Inc.); Honoraria: J.R. Lisse (Merck and Co., Inc.); Stock ownership (other than mutual funds): C.S. Skalky (Merck and Co., Inc.), M.E. Dixon (Merck and Co., Inc.), A.B. Polis (Merck and Co., Inc.), G.P. Geba (Merck and Co., Inc.).
Requests for Single Reprints: Gregory P. Geba, MD, MPH, Merck & Co., Inc., HM-202, PO Box 4, West Point, PA 19486-0004; e-mail, gregory_geba{at}merck.com.
Current Author Addresses: Dr. Lisse: Department of Rheumatology, University of Arizona, 1501 North Campbell, Tuscon, AZ 85724.
Dr. Perlman: Scripps Clinic and Research Foundation, 10666 North Torrey Pines, La Jolla, CA 92037.
Dr. Johansson: Uppsala University, Nyby vårdcentral, Topeliusgatan 18, 754 41 Uppsala, Sweden.
Dr. Shoemaker: Ormond Medical Arts, 77 West Granada Boulevard, Ormond Beach, FL 32174.
Dr. Schechtman: Sun Valley Arthritis Center, Ltd., 6525 West Sack Drive, Glendale, AZ 85308.
Ms. Dixon: Merck & Co., Inc., HM-220, PO Box 4, West Point, PA 19486-0004.
Mr. Polis: Merck & Co., Inc., HM-601, PO Box 4, West Point, PA 19486-0004.
Dr. Mollen: Southwest Health Institute, 4602 North 16th Street, Phoenix, AZ 85016.
Ms. Skalky and Dr. Geba: Merck & Co., Inc., HM-202, PO Box 4,West Point, PA 19486-0004.
Author Contributions: Conception and design: G. Johansson, M.E. Dixon, A.B. Polis, G.P. Geba.
Analysis and interpretation of the data: J.R. Lisse, G. Johansson, C.S. Skalky, A.B. Polis, G.P. Geba.
Drafting of the article: G. Johansson, J. Schechtman, C.S. Skalky, G.P. Geba.
Critical revision of the article for important intellectual content: J.R. Lisse, M. Perlman, G. Johansson, J.R. Shoemaker, J. Schechtman, A.B. Polis, A.J. Mollen, G.P. Geba.
Final approval of the article: J.R. Lisse, M. Perlman, G. Johansson, J.R. Shoemaker, J. Schechtman, A.B. Polis, A.J. Mollen, G.P. Geba.
Provision of study materials or patients: J.R. Lisse, M. Perlman, G. Johansson, J. Schechtman, C.S. Skalky, M.E. Dixon, A.J. Mollen.
Statistical expertise: A.B. Polis, G.P. Geba.
Obtaining of funding: M.E. Dixon.
Administrative, technical, or logistic support: C.S. Skalky, M.E. Dixon.
Collection and assembly of data: G. Johansson, J.R. Shoemaker, C.S. Skalky, M.E. Dixon, A.J. Mollen. ARTICLE
Gastrointestinal Tolerability and Effectiveness of Rofecoxib versus Naproxen in the Treatment of Osteoarthritis
A Randomized, Controlled Trial
For more data, see the following Letter to the Editor: Report of Specific Cardiovascular Outcomes of the ADVANTAGE Trial
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  A. Rabin ADVANTAGE: Merck Does Say "No" Ann Intern Med, November 18, 2008; 149(10): 774 - 774. [Full Text] [PDF]
|
|
|
|
|
|
H. C. Sox and D. Rennie ADVANTAGE: Merck Does Say "No" Ann Intern Med, November 18, 2008; 149(10): 775 - 775. [Full Text] [PDF]
|
|
|
|
|
|
K. P. Hill, J. S. Ross, D. S. Egilman, and H. M. Krumholz The ADVANTAGE Seeding Trial: A Review of Internal Documents Ann Intern Med, August 19, 2008; 149(4): 251 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. C. Sox and D. Rennie Seeding Trials: Just Say "No" Ann Intern Med, August 19, 2008; 149(4): 279 - 280. [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Ross, K. P. Hill, D. S. Egilman, and H. M. Krumholz Guest Authorship and Ghostwriting in Publications Related to Rofecoxib: A Case Study of Industry Documents From Rofecoxib Litigation JAMA, April 16, 2008; 299(15): 1800 - 1812. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Letts and J. Loscalzo Frontiers in Nephrology: Targeting Inflammation Using Novel Nitric Oxide Donors J. Am. Soc. Nephrol., November 1, 2007; 18(11): 2863 - 2869. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P A Scott, G H Kingsley, C M Smith, E H Choy, and D L Scott Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials Ann Rheum Dis, October 1, 2007; 66(10): 1296 - 1304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. O'Byrne, S. Danson, D. Dunlop, N. Botwood, F. Taguchi, D. Carbone, and M. Ranson Combination Therapy With Gefitinib and Rofecoxib in Patients With Platinum-Pretreated Relapsed Non Small-Cell Lung Cancer J. Clin. Oncol., August 1, 2007; 25(22): 3266 - 3273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C Waksman, A. Brody, and S. D Phillips Nonselective Nonsteroidal Antiinflammatory Drugs and Cardiovascular Risk: Are They Safe? Ann. Pharmacother., July 1, 2007; 41(7): 1163 - 1173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. M. Psaty and R. A. Charo FDA Responds to Institute of Medicine Drug Safety Recommendations--In Part JAMA, May 2, 2007; 297(17): 1917 - 1920. [Full Text] [PDF]
|
|
|
|
|
|
Y Yazici and H Yazici A survey of inclusion of the time element when reporting adverse effects in randomised controlled trials of cyclo-oxygenase-2 and tumour necrosis factor {alpha} inhibitors Ann Rheum Dis, January 1, 2007; 66(1): 124 - 127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gaffo, K. G. Saag, and J. R. Curtis Treatment of rheumatoid arthritis Am. J. Health Syst. Pharm., December 15, 2006; 63(24): 2451 - 2465. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Zhang, E. L. Ding, and Y. Song Adverse Effects of Cyclooxygenase 2 Inhibitors on Renal and Arrhythmia Events: Meta-analysis of Randomized Trials JAMA, October 4, 2006; 296(13): 1619 - 1632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G Lippi, M Franchini, G C Guidi, and W F Kean Non-steroidal anti-inflammatory drugs in athletes * Commentary Br. J. Sports Med., August 1, 2006; 40(8): 661 - 663. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Rahme, Y. Toubouti, and E. Hunsche Therapy switching and associated costs in elderly patients receiving COX-2 selective inhibitors or non-selective non-steroidal anti-inflammatory drugs in Quebec, Canada Rheumatology, July 1, 2006; 45(7): 903 - 910. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Correction: Report of Specific Cardiovascular Outcomes of the ADVANTAGE Trial Ann Intern Med, June 20, 2006; 144(12): 943 - 943. [Full Text] [PDF]
|
|
|
|
|
|
D. S. Egilman and A. H. Presler Report of Specific Cardiovascular Outcomes of the ADVANTAGE Trial Ann Intern Med, May 16, 2006; 144(10): 781 - 781. [Full Text] [PDF]
|
|
|
|
|
|
C. Laine and C. D. Mulrow Exorcising Ghosts and Unwelcome Guests Ann Intern Med, October 18, 2005; 143(8): 611 - 612. [Full Text] [PDF]
|
|
|
|
|
|
N. Braunstein and A. Polis Report of Specific Cardiovascular Outcomes of the ADVANTAGE Trial Ann Intern Med, July 19, 2005; 143(2): 158 - 159. [Full Text] [PDF]
|
|
|
|
 |
|
 T.-J. Aw, S. J. Haas, D. Liew, and H. Krum Meta-analysis of Cyclooxygenase-2 Inhibitors and Their Effects on Blood Pressure Arch Intern Med, March 14, 2005; 165(5): 490 - 496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Iadecola and P. B. Gorelick The Janus Face of Cyclooxygenase-2 in Ischemic Stroke: Shifting Toward Downstream Targets Stroke, February 1, 2005; 36(2): 182 - 185. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Shah and B. Thomas Nonsteroidal anti-inflammatory analgesics and gastrointestinal protection in palliative care patients Palliative Medicine, December 1, 2004; 18(8): 739 - 740. [PDF]
|
|
|
|
|
|
K. Kroenke and L. Logio Update in General Internal Medicine Ann Intern Med, August 3, 2004; 141(3): 213 - 220. [Full Text] [PDF]
|
|
|
|
|
|
L. B. Hanauer Tolerability of Rofecoxib versus Naproxen Ann Intern Med, June 15, 2004; 140(12): 1059 - 1059. [Full Text] [PDF]
|
|
|
|
|
|
J. M. Rusche Tolerability of Rofecoxib versus Naproxen Ann Intern Med, June 15, 2004; 140(12): 1059 - 1059. [Full Text] [PDF]
|
|
|
|
|
|
M. L. Jenkinson Tolerability of Rofecoxib versus Naproxen Ann Intern Med, June 15, 2004; 140(12): 1059 - 1060. [Full Text] [PDF]
|
|
|
|
 |
|
 T. D. WARNER and J. A. MITCHELL Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic FASEB J, May 1, 2004; 18(7): 790 - 804. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Stollberger and J. Finsterer Both Thrombotic and Nonthrombotic Cardiovascular and Cerebrovascular Side Effects of Nonsteroidal Anti-Inflammatory Drugs Should Be Considered Stroke, February 1, 2004; 35 (2): e26 - e26. [Full Text] [PDF]
|
|
|
|
 |
|
 Other articles noted: 25 Jul 03 to 7 Nov 03 Evid. Based Nurs., January 1, 2004; 7(1): e1 - 1. [Full Text] [PDF]
|
|
Read all Rapid Responses
Article
